How should we respond to the highly toxogenic NAP1/ribotype 027 strain of Clostridium difficile?

Louie, Thomas J.
October 2005
CMAJ: Canadian Medical Association Journal;10/25/2005, Vol. 173 Issue 9, p1049
Academic Journal
Presents information on Clostridium difficile-associated disease (CDAD). Factors causing the emergence of the Clostridium difficile strain; Background on cephalosporins, the most common inducers of CDAD; Recommended treatment for the disease.


Related Articles

  • Improving the quality of antibiotic prescribing in the NHS by developing a new Antimicrobial Stewardship Programme: Start Smart—Then Focus. Ashiru-Oredope, Diane; Sharland, Mike; Charani, Esmita; McNulty, Cliodna; Cooke, Jonathan // Journal of Antimicrobial Chemotherapy (JAC);Jul2012 Supplement 1, Vol. 67 Issue suppl_1, pi51 

    There has been dramatic change in antibiotic use in English hospitals. Data from 2004 and 2009 show that the focus on reducing fluoroquinolone and second- and third-generation cephalosporin use seems to have been heeded in NHS secondary care, and has been associated with a substantial decline in...

  • Stopping antibacterials increases CDI risk.  // Reactions Weekly;6/11/2011, Issue 1355, p5 

    The article discusses research being done by M. P. Hensgens et al., presented at the 21st European Congress of Clinical Microbiology and Infectious Diseases and the 27th International Congress of Chemotherapy, about the risk for Clostridium difficile infection (CDI) when antibacterial therapy is...

  • Historical Perspectives on Studies of Clostridium difficile and C. difficile Infection. Bartlett, John G. // Clinical Infectious Diseases;1/15/2008 Supplement 1, Vol. 46 Issue 1, pS4 

    The initial period of studies on Clostridium difficile (published during 1978-1980) appeared to provide a nearly complete portfolio of criteria for diagnosing and treating C. difficile infection (CDI). The putative pathogenic role of C. difficile was established using Koch's postulates, risk...

  • Antimicrobial-Associated Risk Factors for Clostridium difficile Infection. Owens Jr., Robert C.; Donskey, Curtis J.; Gaynes, Robert P.; Loo, Vivian G.; Muto, Carlene A. // Clinical Infectious Diseases;1/15/2008 Supplement 1, Vol. 46 Issue 1, pS19 

    Antimicrobial therapy plays a central role in the pathogenesis of Clostridium difficile infection (CDI), presumably through disruption of indigenous intestinal microflora, thereby allowing C. difficile to grow and produce toxin. Investigations involving animal models and studies performed in...

  • Nitazoxanide versus Vancomycin in Clostridium difficile Infection: A Randomized, Double-Blind Study. Musher, Daniel M.; Logan, Nancy; Bressler, Adam M.; Johnson, David P.; Rossignol, Jean-François // Clinical Infectious Diseases;2/15/2009, Vol. 48 Issue 4, pe41 

    Background: Vancomycin is the only US Food and Drug Administration-approved drug for treatment of Clostridium difficile infection (CDI). Metronidazole has been widely used for this purpose but may be inferior to vancomycin, especially for hospitalized patients with severe disease. We report a...

  • Interruption of Recurrent Clostridium difficile-Associated Diarrhea Episodes by Serial Therapy with Vancomycin and Rifaximin. Johnson, Stuart; Schriever, Christopher; Galang, Minerva; Kelly, Ciarán P.; Gerding, Dale N. // Clinical Infectious Diseases;3/15/2007, Vol. 44 Issue 6, p846 

    Eight women who each experienced 4-8 episodes of Clostridium difficile-associated diarrhea were given a 2-week course of rifaximin therapy when they were asymptomatic, immediately after completing their last course of vancomycin therapy. Seven of the 8 patients experienced no further diarrhea...

  • Shigella Corneal Ulceration. Schmiedt, Rudolf; Cimma, Richard // Clinical Pediatrics;Jun1983, Vol. 22 Issue 6, p460 

    This article reports that seudomembranous entrocolitis induced by clostridium difficile toxin after antibiotic treatment is now a well-recognized clinicopathologic entity. More recently, nonantibiotic-associated pseudonieinbranous colitis due to toxin-producing Clostridia has been reported in...

  • Fidaxomicin after Vancomycin for Patients with Multiple C. difficile Recurrences. Watkins, Richard R. // Infectious Disease Alert;Nov2012, Vol. 32 Issue 2, p18 

    Recurrent C. difficile infection (CDI) is a challenging condition to manage. Current guidelines estimate that 25% of patients treated for CDI experience at least 1 additional episode, with those aged 65 years or greater at highest risk. Recurrences are thought to occur either from relapse by the...

  • Predictors of Mortality and Morbidity in Clostridium Difficile Infection. Dixon, Jill; Menezes, Brian F. // Annals of Medicine & Healthcare Research;2009, p577 

    Clostridium Difficile (CD) is implicated in 20 to 30% of patients with antibiotic-associated diarrhoea, in 50 to 70% of those with antibiotic-associated colitis and in more than 90% of those with antibiotic-associated pseudomembranous colitis1-4. The incidence of CD associated diarrhoea ranges...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics